BR112012023660B8 - usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer - Google Patents

usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer

Info

Publication number
BR112012023660B8
BR112012023660B8 BR112012023660A BR112012023660A BR112012023660B8 BR 112012023660 B8 BR112012023660 B8 BR 112012023660B8 BR 112012023660 A BR112012023660 A BR 112012023660A BR 112012023660 A BR112012023660 A BR 112012023660A BR 112012023660 B8 BR112012023660 B8 BR 112012023660B8
Authority
BR
Brazil
Prior art keywords
naphthofuran
compounds
treatment
prodrug
solvate
Prior art date
Application number
BR112012023660A
Other languages
English (en)
Other versions
BR112012023660A2 (pt
BR112012023660B1 (pt
Inventor
Chiang Jia Li
David Leggett
Wei Li
Youzhi Li
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of BR112012023660A2 publication Critical patent/BR112012023660A2/pt
Publication of BR112012023660B1 publication Critical patent/BR112012023660B1/pt
Publication of BR112012023660B8 publication Critical patent/BR112012023660B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

novos métodos para direcionar células-tronco cancerosas a invenção fornece compostos de naftofurano, polimorfos de compostos de naftogurano, compostos de naftofurano na forma de partículas, as composições purificadas que contêm um ou mais compostos de naftofurano, as composições purificadas que contêm um ou mais compostos de naftofurano em forma de partículas, os métodos de produção destes compostos, polimorfos, composições purificadas e/ou formas de partículas de naftofurano, e os métodos de uso destes compostos, polimorfos, composições purificadas e/ou formas de partículas de naftofurano para o tratamento de sujeitos com necessidade dos mesmos.
BR112012023660A 2010-03-19 2011-03-21 usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer BR112012023660B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31588610P 2010-03-19 2010-03-19
US31589010P 2010-03-19 2010-03-19
US61/315,890 2010-03-19
US61/315,886 2010-03-19
US32581410P 2010-04-19 2010-04-19
US61/325,814 2010-04-19
PCT/US2011/029283 WO2011116399A1 (en) 2010-03-19 2011-03-21 Novel methods for targeting cancer stem cells

Publications (3)

Publication Number Publication Date
BR112012023660A2 BR112012023660A2 (pt) 2015-09-15
BR112012023660B1 BR112012023660B1 (pt) 2021-05-18
BR112012023660B8 true BR112012023660B8 (pt) 2021-05-25

Family

ID=47678420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012023660A BR112012023660B8 (pt) 2010-03-19 2011-03-21 usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer

Country Status (9)

Country Link
US (2) US9730909B2 (pt)
EP (1) EP2547205B1 (pt)
JP (1) JP2013522326A (pt)
CN (1) CN103025159A (pt)
AU (1) AU2011227023B2 (pt)
BR (1) BR112012023660B8 (pt)
CA (2) CA2793527A1 (pt)
RU (1) RU2591823C2 (pt)
WO (1) WO2011116399A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2569215T3 (es) 2007-09-10 2016-05-09 Boston Biomedical, Inc. Un nuevo grupo de inhibidores de la ruta de Stat3 e inhibidores de la ruta de las células madre del cáncer
CN107721958A (zh) * 2010-03-19 2018-02-23 北京强新生物科技有限公司 靶向癌症干细胞的新的化合物和组合物
BR112015025347A2 (pt) 2013-04-09 2017-07-18 Boston Biomedical Inc 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer
CN106163284A (zh) 2014-02-07 2016-11-23 北京强新生物科技有限公司 3‑取代的羰基萘并[2,3‑b]呋喃衍生物或其药学上可接受的盐
DK3153508T3 (da) 2014-06-09 2020-05-18 Kyoto Pharma Ind Naphthofuranderivater til anvendelse som anticancermidler
AU2016249157A1 (en) 2015-04-17 2017-11-02 Boston Biomedical, Inc. Methods for treating cancer
TW201713327A (zh) 2015-04-17 2017-04-16 波士頓生醫公司 治療癌症之方法
CA2988126A1 (en) * 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
CN109069469A (zh) 2016-01-20 2018-12-21 北京强新生物科技有限公司 治疗癌症的方法
CA3029596A1 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
US10926226B2 (en) * 2018-03-08 2021-02-23 ExxonMobil Research & Engineering Company Company Functionalized membranes and methods of production thereof
KR20210076951A (ko) 2018-10-12 2021-06-24 1글로브 바이오메디칼 씨오., 엘티디. 화학요법 불응성 암을 치료하기 위한 신규한 조합 방안
CN111825644B (zh) * 2019-04-18 2023-07-28 中国医学科学院药物研究所 2,3-二氢萘并[2,3-b]呋喃-4,9-二酮类化合物及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
AU2736400A (en) 1999-01-27 2000-08-18 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
MXPA02000828A (es) 1999-08-02 2002-07-30 Hoffmann La Roche Nuevos antagonistas retinoiides selectivos.
JP2001097860A (ja) * 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
AU2002307217A1 (en) 2001-03-28 2002-10-15 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
US20040092428A1 (en) 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
CN1310652C (zh) * 2001-11-29 2007-04-18 特拉科斯有限公司 用体外光提取法和/或凋亡细胞对被试者进行预治疗的方法
JP2005526084A (ja) 2002-03-15 2005-09-02 ナットイムネ・アクティーゼルスカブ マンノース結合レクチンを含む医薬組成物
WO2004026253A2 (en) * 2002-09-17 2004-04-01 Arqule, Inc. Novel lapacho compounds and methods of use thereof
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
EP2481814A3 (en) 2003-06-09 2012-10-10 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
WO2005058829A1 (en) 2003-12-11 2005-06-30 Board Of Regents, The University Of Texas System Compounds for treatment of cell proliferative diseases
CA2563305A1 (en) 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
CN101106983A (zh) 2004-11-24 2008-01-16 诺瓦提斯公司 JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
CA2599393A1 (en) 2005-02-25 2006-08-31 The Regents Of The University Of Michigan Small molecule inhibitors of stat3 and the uses thereof
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101142202A (zh) * 2005-03-16 2008-03-12 太日保日本株式会社 抗癌化合物及其中间体和生产方法
JP2006290871A (ja) 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
US20070243192A1 (en) 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
EP2007714A2 (en) 2006-03-31 2008-12-31 The Board of Regents of The University of Texas System Orally bioavailable caffeic acid related anticancer drugs
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
WO2008094321A2 (en) 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法
ES2569215T3 (es) * 2007-09-10 2016-05-09 Boston Biomedical, Inc. Un nuevo grupo de inhibidores de la ruta de Stat3 e inhibidores de la ruta de las células madre del cáncer
WO2009060282A2 (en) 2007-11-06 2009-05-14 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
CN107721958A (zh) * 2010-03-19 2018-02-23 北京强新生物科技有限公司 靶向癌症干细胞的新的化合物和组合物

Also Published As

Publication number Publication date
RU2591823C2 (ru) 2016-07-20
CA2946890A1 (en) 2011-09-22
US20130028944A1 (en) 2013-01-31
JP2013522326A (ja) 2013-06-13
US9730909B2 (en) 2017-08-15
AU2011227023A1 (en) 2012-09-27
US20170319537A1 (en) 2017-11-09
AU2011227023B2 (en) 2015-05-28
CA2793527A1 (en) 2011-09-22
EP2547205A1 (en) 2013-01-23
EP2547205B1 (en) 2024-03-20
EP2547205A4 (en) 2013-08-14
RU2012144420A (ru) 2014-04-27
CN103025159A (zh) 2013-04-03
BR112012023660A2 (pt) 2015-09-15
WO2011116399A1 (en) 2011-09-22
BR112012023660B1 (pt) 2021-05-18

Similar Documents

Publication Publication Date Title
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
GT201400111A (es) Triazolopiridinas sustituidas
CL2012002319A1 (es) Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras.
EA201690752A1 (ru) Ингибиторы g12c kras
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
IL232267A (en) Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
BR112015009216A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
UY33241A (es) ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
EA201491356A1 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
BR112015018168A2 (pt) inibidores de rock suaves
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
DOP2015000170A (es) Compuestos químicos
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
WO2013040227A3 (en) Therapeutic compounds
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/16 , A61K 31/35

Ipc: A61K 31/35 (2006.01), A61K 31/27 (2006.01), A61K 3

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/03/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/03/2011 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF